128$/KG
108$/KG
liposomal NMN 70% is a premium-grade, liposomal-encapsulated form of β-nicotinamide mononucleotide (β-NMN), the biologically active isomer that serves as a direct substrate for NAD+ biosynthesis in the salvage pathway. NAD+ (nicotinamide adenine dinucleotide) is a critical redox cofactor and signaling molecule that regulates cellular metabolism, genome stability, and stress responses, with levels declining significantly during aging. By delivering NMN in a phospholipid bilayer delivery system, this product addresses the fundamental limitations of conventional NMN: its structural instability and limited oral bioavailability.
NMN is inherently unstable in aqueous environments and susceptible to degradation into nicotinamide (NAM) under physiological conditions. Conventional oral NMN achieves limited bioavailability due to rapid degradation in the gastrointestinal tract and inefficient cellular uptake.
Liposomal encapsulation provides three critical advantages:
1. Structural Protection — The phospholipid bilayer shields NMN from enzymatic degradation and hydrolysis during digestive transit, preserving its intact molecular structure until reaching target cells.
2. Enhanced Cellular Uptake — liposomes fuse directly with cell membranes, facilitating efficient cytoplasmic delivery of NMN and bypassing passive diffusion limitations. Encapsulation efficiency can be optimized through controlled manufacturing processes.
3. Improved Stability — Liposomal encapsulation significantly enhances NMN stability, preventing its degradation into inactive nicotinamide and maintaining potency throughout shelf life.
| Field | Details |
|---|---|
| Product Name | Liposomal NMN 70% |
| CAS No. | 1094-61-7 |
| Assay Method | LC-MS/MS (stereospecific α-/β-NMN quantification); HPLC-UV for routine quality control |
| Active Ingredient | β-Nicotinamide Mononucleotide (β-NMN) |
| Purity | ≥ 70% (HPLC) |
| Appearance | White to off-white powder |
| Dosage Form | Liposomal powder, water-dispersible |
| Application | Healthy aging support, NAD+ restoration, cellular Energy Metabolism, mitochondrial function, metabolic health, neuroprotection |
| Extract Source | Enzymatic synthesis (non-animal, non-plant derived; green manufacturing approach) |
| Recommended Dosage | 50–250 mg β-NMN per serving (clinical studies have demonstrated safety at 250 mg daily) |
| Lead Time | In stock: 3–5 business days; Bulk orders: 2–3 weeks |
| Shipping Method | International Express (FedEx/DHL/UPS); Air and sea shipping available; ships worldwide including remote areas |
NMN Encyclopedia — Scientific Background
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a key biosynthetic intermediate of nicotinamide adenine dinucleotide (NAD+). The compound exists as two stereoisomers—α-NMN and β-NMN—differing only at the anomeric carbon of the ribose moiety. Among them, β-NMN is the biologically active form that serves as a direct substrate for NAMPT in the NAD+ salvage pathway. α-NMN is not recognized by NAD+ biosynthetic enzymes and lacks clearly defined physiological function.
NAD+ is an essential coenzyme involved in redox reactions, Energy Metabolism, and DNA repair. Its levels decline significantly with age, contributing to vascular dysfunction, metabolic impairment, and cellular aging. NMN supplementation has been demonstrated to restore depleted NAD+, enhance mitochondrial function, facilitate neuroprotection, and reduce metabolic impairment associated with aging and chronic disease states.
A 12-week randomized, double-blind, placebo-controlled trial in 36 healthy middle-aged adults demonstrated that daily NMN supplementation (250 mg) was safe, with no adverse effects observed. Serum analysis revealed a significant increase in nicotinamide levels, indicating enhanced NAD+ metabolism. Vascular assessment showed that brachial-ankle pulse wave velocity decreased by 25.1 cm/s in the NMN group versus +6.4 cm/s in the placebo group, corresponding to an approximate 2-year reduction in vascular age. Subgroup analysis further showed significant improvements in participants with higher BMI and glucose levels.
NMN presents significant formulation challenges due to its high polarity, poor solubility in organic solvents, and structural instability. The compound is susceptible to degradation into nicotinamide under physiological conditions. Conventional oral NMN achieves limited bioavailability due to enzymatic degradation and inefficient cellular uptake.
liposomal encapsulation addresses these limitations through a biomimetic phospholipid bilayer that protects NMN during digestive transit, facilitates direct membrane fusion for cellular uptake, and prevents degradation into inactive nicotinamide. The result is enhanced stability, improved bioavailability, and more efficient NAD+ restoration.
NMN is widely commercialized as a dietary supplement ingredient. The β-NMN isomer is the biologically active form used in clinical research and commercial products. Formulators should verify local regulatory requirements, as NMN’s regulatory status varies by region.
128$/KG
108$/KG
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）